Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07124884 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab

Study acronym: COLOSOTO
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
5-fluorouracil (5-FU) is a standard of care in frail/elderly patients with an unresectable colorectal adenocarcinoma (CRC) in first-line setting. Panitumumab plus Sotorasib are promising in advanced line in KRAS G12C mutated CRC. In this study, We assess the safety and efficacy of 5FU combination with Panitumumab and Sotorasib as first-line treatment in frail/elderly patients with unresectable KRAS G12C mutated CRC
Trial Details
NCT Number NCT07124884
Lead Sponsor Federation Francophone de Cancerologie Digestive
Collaborators: Northwest Oncology Cooperative Group(GONO), Arbeitsgemeinschaft fur Internistische Onkologie, Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Conditions
(from sponsor)		 Colorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer
Related terms Colorectal Neoplasms
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov